Novo Nordisk's Litigation Against Compounding Pharmacies: A Tracker

Novo Nordisk has pursued civil litigation against a number of compounding pharmacies, medical spas, and telehealth companies, generally alleging false advertising, trademark issues, or the sale of misbranded products claiming to be or to contain semaglutide.

These are private civil lawsuits brought by the manufacturer, distinct from FDA regulatory enforcement, though the two can address overlapping conduct — a defendant could face both an FDA warning letter and a Novo Nordisk lawsuit over similar underlying practices.

Outcomes have included settlements, injunctions, and dismissals depending on the specific claims and evidence in each case. Court records and Novo Nordisk's own legal announcements are the primary sources for tracking specific case status.